E Fund Management Co. Ltd. Makes New Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

E Fund Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 17,844 shares of the company’s stock, valued at approximately $31,000.

A number of other institutional investors have also made changes to their positions in the stock. Creative Planning bought a new stake in Taysha Gene Therapies during the third quarter worth approximately $28,000. Intech Investment Management LLC acquired a new stake in shares of Taysha Gene Therapies in the third quarter worth $85,000. MetLife Investment Management LLC boosted its holdings in shares of Taysha Gene Therapies by 81.9% during the 3rd quarter. MetLife Investment Management LLC now owns 76,037 shares of the company’s stock worth $153,000 after buying an additional 34,243 shares during the period. Franklin Resources Inc. bought a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth $201,000. Finally, Privium Fund Management B.V. grew its stake in Taysha Gene Therapies by 21.8% in the 3rd quarter. Privium Fund Management B.V. now owns 120,000 shares of the company’s stock valued at $241,000 after buying an additional 21,500 shares during the last quarter. 77.70% of the stock is owned by institutional investors.

Taysha Gene Therapies Price Performance

Shares of TSHA stock opened at $1.75 on Monday. The company has a market capitalization of $358.75 million, a P/E ratio of 2.78 and a beta of 0.91. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies, Inc. has a 12 month low of $1.19 and a 12 month high of $4.32. The stock has a 50 day moving average of $1.66 and a two-hundred day moving average of $1.95.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. The firm had revenue of $2.02 million during the quarter, compared to analysts’ expectations of $2.05 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. As a group, equities analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on TSHA. JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Chardan Capital reissued a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a report on Thursday, February 27th. Canaccord Genuity Group upped their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $6.63.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.